The Influence of Radiology in Oncology: Targeted Treatment Approaches

Alkhalaf Moussa Kazem [1], Yousef Saleh Alhasawi [2], Hussain Abdullah Alaboud [3], Almutawah ,Bader Hajia [4], Ali Abdul Mohsen Alkhalaf [5], Moayyed younes Ghawas [6], Hussain Abdullah Al Baqshi [7], Omran Mohammed Bohulaiqa [8] , Ahmed Ali ALsaleh [9], Mohammed Saleh Alshehab [10]

1- Radiology technologist, King fahad hospital, Hofuf, Saudi Arabia
2- Radiology technologist , King fahad hospital, Hofuf, Saudi Arabia
3- Radiology technologist , King fahad hospital, Hofuf, Saudi Arabia
4- Radiology technologist , King Fahad hospital, Hofuf, Saudi Arabia
5- Radiotechnologist, King fahad hofuf hospital, Saudi Arabia
6- Radiotechnologist, King Fahad Hufof Hospital, Saudi Arabia
7- Radiology technologist, King Faisal general Hospital, Saudi Arabia
8- Radiology technologist, King Fahad Hafuf Hospital, Saudi Arabia
9- Radiology technician, King fahad hofuf hospital, Saudi Arabia
10- Radiology Technologies, King Fahad Hospital, Hofof, Saudi Arabia

Abstract:

Radiology plays a crucial role in oncology by enhancing the accuracy of diagnosis and treatment planning through advanced imaging techniques. Modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) allow for detailed visualization of tumors, enabling healthcare professionals to assess tumor size, location, and metabolic activity. These imaging methods not only aid in the initial diagnosis but also in monitoring treatment response and detecting recurrences. The integration of radiology in oncology enhances the ability to tailor targeted treatment approaches, allowing for more personalized care that can significantly improve patient outcomes. Targeted treatment approaches in oncology often rely on radiological findings to guide therapies such as radiation therapy, chemotherapy, and immunotherapy. Personalized treatment plans can be developed based on tumor characteristics evidenced through imaging studies, leading to more effective use of resources and reduced side effects. Additionally, emerging technologies like radiomics, which analyzes imaging data to extract quantitative features, are paving the way for precision medicine in oncology. As radiology continues to evolve, its influence on targeted treatment strategies will likely expand, promoting innovative approaches to combat cancer more effectively.

Keywords: Radiology, Oncology, Imaging techniques, Diagnosis, Tumor characterization, Treatment planning, Targeted treatment approaches, Radiation therapy, Precision medicine, Radiomics

Introduction:

The field of oncology has undergone a remarkable transformation over the past few decades, evolving from traditional treatment modalities to more precise and personalized methods aimed at improving patient outcomes. This evolution has been significantly influenced by advancements in radiology, a branch of medicine that employs imaging techniques to diagnose, monitor, and treat diseases. As oncology increasingly embraces targeted treatment approaches, it is essential to understand the pivotal role that radiology plays in this dynamic landscape. By integrating advanced imaging modalities with innovative therapeutic strategies, radiology not only enhances the accuracy of cancer diagnosis but also facilitates the development of targeted interventions that are tailored to the unique characteristics of individual tumors [1].

Fundamentally, radiology has redefined the diagnostic paradigm in oncology by providing detailed visual insights into tumor biology and behavior. Techniques such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound play critical roles in cancer detection, staging, and response assessment. Radiologists, through these imaging modalities, can elucidate the anatomic and metabolic features of tumors, which are crucial for determining the appropriate treatment pathways. The emergence of radiogenomics, the study of the relationship between imaging phenotypes and genetic characteristics of tumors, further underscores the synergy between radiology and personalized medicine. By correlating imaging findings with molecular data, clinicians can identify specific biomarkers that guide targeted therapies, allowing for more effective and individualized oncology care [2].

The growing field of targeted therapies—agents that specifically attack cancer cells while sparing normal tissues—has been greatly enhanced by the insights provided through radiological imaging. Traditional cancer treatments such as chemotherapy and radiation therapy often affect both cancerous and healthy cells, resulting in a range of side effects that can significantly impact patients' quality of life. In contrast, targeted therapies are designed to exploit specific vulnerabilities in cancer cells based on their genetic makeup or molecular alterations. Radiologic assessments are essential in this context, as they enable oncologists to determine the suitability of patients for targeted treatment options by assessing tumor heterogeneity, molecular signatures, and potential resistance mechanisms [3].

One compelling illustration of the interplay between radiology and targeted treatment approaches in oncology involves the use of imaging in the selection and monitoring of patients for therapies such as monoclonal antibodies, small molecule inhibitors, and immunotherapies. For instance, imaging biomarkers derived from PET scans can help predict patient responses to therapies targeting specific signaling pathways, such as the phosphoinositide 3-kinase (PI3K) pathway or the programmed death-1 (PD-1) receptor. By identifying patients who are more likely to benefit from these targeted agents, radiology significantly contributes to the optimization of treatment protocols and avoids exposing patients to ineffective therapies and their associated side effects [4].

Imaging Modalities: Tools for Tumor Assessment:

The assessment of tumors is a crucial aspect of oncology, involving the detection, characterization, staging, and monitoring of cancerous growths. Accurate imaging is essential for achieving these objectives, as it enables healthcare professionals to visualize the internal structures of the body, assess the extent of disease, and formulate appropriate treatment plans. Various imaging modalities are employed in tumor assessment, each offering unique advantages and limitations [5].

X-ray imaging is one of the earliest and most widely used imaging modalities in medicine. It employs ionizing radiation to produce images of the body's internal structures. In the context of tumor assessment, X-rays can be beneficial for identifying certain types of masses, particularly in the chest and skeleton. For example, a chest X-ray can reveal lung tumors or metastases in the lungs, while skeletal surveys use X-rays to detect bone lesions in patients with known malignancies [6].

Despite its utility, X-ray imaging is limited in its resolution and specificity. Many benign conditions can mimic tumors on X-rays, leading to potential misinterpretation. Additionally, X-ray images fail to provide detailed information on the tumor's cellular composition or proximity to surrounding structures. Consequently, while X-rays are valuable for initial evaluations, supplementary imaging modalities are often required for a more comprehensive analysis [7].

Computed tomography (CT) is a more advanced imaging modality that employs a series of X-ray images taken from different angles to create cross-sectional views of the body. CT scans provide enhanced detail and can reveal the size, shape, and location of tumors, making them invaluable for staging cancer and planning surgical interventions. CT imaging is particularly effective for assessing lung, liver, pancreatic, and abdominal tumors [7].

One of the essential advantages of CT scans is their speed; they can be completed in a matter of minutes, allowing for rapid diagnosis and treatment planning. Furthermore, the use of contrast agents can improve the visibility of tumors and surrounding tissues. However, CT scans expose patients to higher doses of radiation compared to conventional X-rays, raising concerns about the cumulative effects of radiation exposure in patients requiring multiple scans over time [8].

Magnetic resonance imaging (MRI) employs strong magnetic fields and radio waves to generate detailed images of soft tissues within the body. Unlike X-ray and CT, MRI does not use ionizing radiation, which makes it a safer option for certain patient populations, such as pregnant women or individuals requiring multiple imaging studies [8].

MRI is particularly useful for assessing tumors in the brain, spine, and pelvis due to its superior soft-tissue contrast. For example, in brain tumors, MRI is essential for distinguishing between tumor types and assessing tumor infiltration into surrounding tissues. Moreover, advanced MRI techniques, such as functional MRI (fMRI) and diffusion-weighted imaging (DWI), can provide valuable information about tumor metabolism and cellularity, aiding in both diagnosis and treatment planning [9].

However, MRI has limitations, such as its long acquisition times and susceptibility to motion artifacts. Additionally, certain patients with metallic implants or claustrophobia may not be suitable candidates for MRI studies, which necessitates the consideration of alternative imaging modalities in such cases [9].

Positron emission tomography (PET) is a functional imaging technique that assesses metabolic activity within tissues. It uses radiotracers, often glucose analogs labeled with positron-emitting isotopes (like Fluorodeoxyglucose, or FDG), to visualize areas of increased metabolic activity, which may indicate tumor presence or recurrence [10].

PET scans are particularly valuable in oncology for staging cancers, assessing treatment response, and detecting metastases. The ability to visualize metabolic changes often provides insights that structural imaging cannot capture. For instance, a PET scan may identify active cancer cells even when structural imaging shows no obvious tumor mass [11].

However, PET scans also have limitations. The sensitivity of PET can lead to false positives in cases of infection or inflammation, which may complicate diagnosis. Additionally, PET is typically used in conjunction with CT (PET/CT) to provide anatomical localization of metabolic hot spots. This hybrid imaging approach enhances diagnostic accuracy but also increases the overall radiation dose to the patient [11].

Ultrasound is a non-invasive imaging technique that uses high-frequency sound waves to produce real-time images of soft tissues and fluid-filled structures in the body. It is particularly useful in guiding biopsies and for assessing tumors in the abdomen, pelvis, and breast [12].

The main advantages of ultrasound include its safety, portability, and cost-effectiveness. It does not involve ionizing radiation, making it suitable for use in sensitive populations. Moreover, ultrasound provides dynamic imaging, allowing for real-time assessment of tumor characteristics and blood flow [13].

Nevertheless, ultrasound has its limitations. Its effectiveness can be operator-dependent, and it may struggle to visualize deep-seated tumors or those in complex anatomical locations. Additionally, the resolution of ultrasound is generally inferior to that of CT and MRI [13].

The Role of Radiology in Early Cancer Detection:

Cancer remains one of the leading causes of morbidity and mortality worldwide, prompting ongoing efforts to improve early detection and diagnosis. With advances in technology and imaging techniques, radiology has emerged as a pivotal discipline in oncology, offering tools that are essential for identifying malignant transformations at the earliest possible stage. The role of radiology in early cancer detection encompasses a variety of imaging modalities, the interpretation of results, and the integration of radiological findings with clinical practices [13].

The field of radiology has undergone remarkable transformations over the past few decades, significantly refining imaging methodologies. The primary imaging modalities utilized in cancer detection include X-rays, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and positron emission tomography (PET) [14].

X-rays, while considered one of the oldest forms of imaging, continue to facilitate the detection of certain cancers such as breast cancer through mammography. This specific type of X-ray is designed for breast tissue examination and is instrumental in early diagnosis, especially in asymptomatic populations. The establishment of routine mammography screening has proven to reduce mortality rates significantly, underscoring its role in catching breast cancer in its initial stages [14].

CT scans have revolutionized cancer detection by providing cross-sectional images of the body, allowing for detailed visualization of tumors. This modality is particularly useful for detecting lung cancer, abdominal tumors, and cancers that affect lymph nodes. CT scans can recognize small lesions and metastases that may elude other imaging modalities [15].

MRI, with its superior soft tissue contrast, plays a crucial role in the detection of brain tumors, prostate cancer, and gynecological cancers. Furthermore, MRI's ability to exclude non-cancerous conditions enhances its diagnostic yield, making it an invaluable tool for oncologists [16].

Ultrasound, a non-invasive and radiation-free technique, is frequently employed for examining organs such as the liver and kidneys. Its real-time capabilities allow physicians to assess blood flow and tissue characteristics, helping to identify abnormalities that may indicate cancer early [16].

Oncologists often use PET scans in conjunction with CT imaging (PET/CT) to evaluate metabolic activity in tissues. Malignant cells typically demonstrate increased glucose metabolism, which can be detected via radioactive tracers. This combination of anatomical and functional imaging provides a robust framework for assessing not only the presence but also the progression of cancer [17].

The benefits of early cancer detection are profound, and they emphasize the role of radiology in enhancing patient outcomes. Early-stage cancers typically have better prognoses and more treatment options available, allowing for less aggressive interventions. The American Cancer Society reports that five-year survival rates for localized cancers are significantly higher relative to those diagnosed at advanced stages. For instance, localized breast cancer has a five-year survival rate of about 99%, whereas metastatic breast cancer has a survival rate that diminishes to 27%. The differentiation in survival rates highlights the crucial nature of early detection efforts facilitated by radiological advancements [18].

The detection of cancer through imaging is only as effective as the interpretation of those images. Radiologists, specialists trained to analyze complex imaging results, play a critical role in identifying abnormal findings. They employ a combination of technological expertise and clinical acumen to discern subtle differences indicative of malignancy [18].

Once imaging results are acquired, radiologists collaborate closely with oncologists and other healthcare professionals to formulate a comprehensive plan of action. They assist in clarifying imaging findings, providing differential diagnoses, and helping determine whether additional imaging or follow-up is necessary. This multidisciplinary approach enhances the overall treatment paradigm for patients at risk of cancer [19].

Additionally, the rapid advancements in artificial intelligence and machine learning are beginning to complement traditional radiology practices. AI can assist radiologists in identifying patterns and improving diagnostic accuracy, allowing physicians to prioritize cases and expedite critical diagnoses. Although these technologies are not replacements for human expertise, their integration signifies an exciting frontier in cancer diagnostics [19].

Despite the immense potential of radiology in early cancer detection, there are inherent limitations and challenges associated with its implementation. The risk of false positives and negatives remains a pressing concern. A false positive may lead to unnecessary anxiety, invasive procedures, and increased healthcare costs, while a false negative can result in a critical delay in treatment. Hence, the specificity and sensitivity of imaging modalities must continually evolve through ongoing research and technological improvements [20].

Moreover, access to advanced imaging services is often limited by geographic and socioeconomic factors. Rural areas may lack the necessary facilities or trained personnel, contributing to disparities in cancer screening and detection. Efforts to democratize access to imaging technologies are essential to ensure that all populations can benefit from early cancer detection initiatives [21].

Targeted Treatment Strategies Enhanced by Imaging:

In recent years, the integration of advanced imaging technologies with targeted treatment strategies has revolutionized the landscape of modern medicine. This dynamic combination has provided healthcare practitioners with innovative tools to deliver patient-specific therapies, resulting in improved outcomes for a variety of diseases, particularly cancer and chronic conditions [22].

Targeted treatment strategies represent a paradigm shift from traditional therapies, such as chemotherapy or broad-spectrum pharmaceuticals, that often produce systemic side effects and lack specificity. Instead, targeted therapies focus on particular molecular targets associated with disease, effectively tailoring therapeutic interventions to the individual patient's unique pathology. In oncology, targeted treatments often utilize specific genetic or molecular markers found in tumor cells to identify which patients will benefit most from particular interventions [22].

Additionally, targeted therapies can also include monoclonal antibodies, small molecule inhibitors, and gene therapies, all designed to attack disease cells while sparing normal, healthy cells. This approach not only enhances efficacy but also minimizes side effects, improving the patient's quality of life during treatment [23].

Imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and ultrasound, play a pivotal role in facilitating targeted treatment strategies. These imaging modalities enhance the precision of targeted therapies by enabling accurate diagnosis, treatment planning, real-time monitoring, and assessment of treatment response. A few key ways imaging contributes to targeted treatments include:

Early and accurate diagnosis is essential for effective targeted treatment. Advanced imaging techniques can identify tumors at earlier stages, enabling the immediate initiation of therapies tailored to the specific characteristics of the tumor. For example, functional imaging provides valuable insights into tumor biology by allowing clinicians to observe metabolic activity, cellular density, and vascularization of tumors. PET scans can be particularly useful in this context, enabling the visualization of metabolic changes that occur before significant anatomical changes manifest [24].

Once a diagnosis is established, imaging technologies assist in developing a precision treatment plan. High-resolution imaging allows oncologists to visualize tumor location, size, and surrounding structures, ensuring that therapies are directed appropriately. In radiation therapy, imaging is critical for accurately targeting tumor sites while minimizing damage to surrounding healthy tissue, a feat achieved through technologies such as image-guided intensity-modulated radiation therapy (IG-IMRT) [25].

One of the most significant advantages of integrating imaging modalities with targeted therapies is the ability to monitor treatment response in real time. Technologies such as MRI and PET can provide insight into how a tumor is responding to the intended therapy, allowing clinicians to make timely adjustments if necessary. For instance, if a particular targeted treatment appears ineffective, imaging can identify alternative strategies based on evolving disease characteristics—such as drug resistance or changes in tumor biology [26].

Several compelling case studies demonstrate the profound impact of imaging-enhanced targeted treatment strategies [26].

In breast cancer treatment, a combination of MRI and molecular imaging techniques is employed to identify tumor response to therapies and guide surgical decisions. MRI is particularly effective in evaluating the extent of disease pre-operation, helping to inform decisions regarding lumpectomy versus mastectomy. Moreover, in clinical trials, PET imaging has been utilized to assess metabolic response to therapies such as trastuzumab (Herceptin) for HER2-positive breast cancer, where early detection of metabolic changes could indicate patient prognosis and therapeutic efficacy [27].

For prostate cancer, imaging improvement has been notable. Advanced imaging techniques like multiparametric MRI provide insights into the aggressiveness of the cancer before intervention. Additionally, targeted biopsy procedures benefit from real-time imaging, allowing for accurate sample acquisition from suspicious areas identified during imaging. The strategic use of PSMA PET imaging, which targets prostate-specific membrane antigen, has significantly enhanced the precision of detecting metastatic lesions contributing to better management and treatment planning [28].

While the integration of imaging technologies with targeted treatment strategies presents numerous benefits, several challenges remain. The complexity of multi-modal imaging requires considerable expertise and may result in discrepancies between imaging interpretations. The expenses associated with advanced imaging modalities can also hinder accessibility, particularly in resource-limited settings [29].

Furthermore, data integration and interdisciplinary collaboration among oncologists, radiologists, and molecular biologists are vital but can be complex. As healthcare systems evolve, fostering collaborative environments and investing in training will be critical in leveraging these advanced strategies successfully [29].

Looking to the future, the potential of integrating imaging with targeted treatment strategies appears boundless. Advances in artificial intelligence and machine learning are expected to transform how imaging data are analyzed, facilitating the rapid identification of patterns that may not be visible to the human eye. Liquid biopsy technologies, which detect circulating tumor DNA through blood samples, are poised to complement imaging techniques, providing real-time insights into genetic changes without the need for invasive procedures [30].

Overall, as our understanding of disease mechanisms deepens and imaging technologies continue to evolve, the pursuit of personalized medicine will advance, improving patient outcomes through the enhanced precision of targeted treatment strategies [30].

Radiomics: The Future of Personalized Oncology:

In recent years, the field of oncology has witnessed a transformative shift with the advent of advanced imaging technologies and sophisticated analytical techniques. Among these innovations, radiomics has emerged as a frontier in personalized medicine, promising to enhance cancer diagnosis, treatment, and monitoring. By extracting large amounts of quantitative features from medical imaging data, radiomics holds the potential to support tailored treatment strategies and improve patient outcomes [31].

Radiomics refers to the process of converting medical imaging data into quantitative information that can be analyzed computationally. It involves the extraction of a multitude of features from images such as CT scans, PET scans, and MRIs. These features encompass various characteristics of the tumor, including its shape, texture, size, and intensity variations. The fundamental premise of radiomics is that these quantitative measurements reflect the underlying biology of tumors, enabling clinicians to derive insights that go beyond traditional imaging interpretation [31].

The practice of radiomics typically involves several steps. First, images are acquired through routine imaging modalities. Second, pre-processing techniques are employed to normalize and enhance the quality of the images. Third, quantitative features are extracted with the help of algorithms designed for texture analysis and machine learning. Finally, the extracted features are analyzed to identify patterns and correlations with clinical outcomes, genomics, and other biological data [31].

The potential applications of radiomics in oncology are extensive, encompassing various stages of cancer management. One significant area of application is in cancer diagnosis and stratification. Radiomics can assist in differentiating between malignant and benign lesions and can provide insights into tumor aggressiveness. Several studies have demonstrated that radiomic features can effectively predict tumor grade, histological subtype, and even specific genetic mutations associated with certain cancers [32].

Another vital application of radiomics is in treatment response evaluation. By analyzing imaging data before and after treatment, radiomics can help assess which patients are more likely to benefit from specific therapies and provide real-time updates on treatment efficacy. This capability can facilitate adaptive treatment strategies, allowing clinicians to modify therapeutic approaches based on the observed responses of individual patients [32].

Furthermore, integrative radiomics can be employed to personalize treatment regimens by considering the tumor's biological behavior. For example, machine learning models that incorporate radiomic features alongside clinical data can predict which patients are likely to experience remission and recurrence, ultimately guiding decisions in radiation therapy, immunotherapy, and chemotherapy [32].

Despite its immense potential, the application of radiomics in clinical settings is not without challenges. One of the major hurdles is the standardization of image acquisition and processing protocols. Variability in imaging techniques, scanner settings, and patient preparation can lead to inconsistencies in the extracted features. To ensure reproducibility and generalizability of radiomic data, it is essential to establish standardized methodologies that can be widely adopted across different institutions [32].

Another significant challenge is the integration of radiomic data with other omics data (genomics, proteomics, metabolomics) and electronic health records to provide a comprehensive view of patient profiles. Combining diverse data sources requires advanced computational techniques and robust analytical frameworks capable of handling high-dimensional datasets [33].

The interpretability of radiomic models also poses a challenge. While machine learning algorithms can identify complex patterns in data, elucidating the biological significance of these findings remains a critical task. Clinicians must be equipped to understand the implications of radiomic biomarkers in the context of patient care, necessitating ongoing education and collaboration between oncologists and data scientists [34].

The future of radiomics in personalized oncology is promising, with ongoing research aimed at overcoming the aforementioned challenges. As technological advancements continue to unfold, the integration of artificial intelligence (AI) and machine learning techniques into radiomics will likely enhance the ability to analyze massive datasets, identify novel biomarkers, and predict treatment responses [35].

Additionally, as more clinical trials evaluate the utility of radiomics in different cancer types, the accumulated evidence will bolster the adoption of radiomic biomarkers in routine clinical practice. Regulatory bodies are also beginning to recognize the significance of radiomics, with efforts to develop guidelines for its use in clinical decision-making [35].

Moreover, as personalized medicine continues to gain traction, the role of radiomics will inevitably expand. By combining imaging data with genetic information and patient characteristics, clinicians will be empowered to offer highly individualized treatment plans tailored to the unique features of each patient's cancer. This holistic approach to patient management will enhance not only the efficacy of treatments but also improve patient quality of life by minimizing unnecessary exposure to ineffective interventions [36].

Monitoring Treatment Response through Radiological Techniques:

The landscape of modern medicine has evolved significantly with the advent of sophisticated imaging technologies, which are critical to diagnosing, monitoring, and evaluating treatment responses in patients with various medical conditions, particularly cancer and other chronic diseases [36].

Monitoring treatment response is essential in tailoring therapy to individual patients, optimizing outcomes, and minimizing unnecessary side effects. Effective treatment response assessment allows healthcare providers to conclude whether a given therapy is effective or whether the treatment strategy needs adjustment. In oncology, for example, early detection of treatment failure can lead to timely alterations in therapeutic approaches, potentially improving survival rates and quality of life [37].

Accurate evaluation of treatment response can also provide vital prognostic information. Marked changes in tumor size or metabolic activity may indicate a positive response to therapy, while stable or progressive disease may necessitate a change in the treatment regimen. Radiological techniques serve as a cornerstone in this evaluative process, guiding clinical decisions and enhancing patient management [38].

X-rays remain one of the most fundamental imaging techniques in clinical practice. While typically not the primary modality for monitoring treatment response, they are frequently employed in the evaluation of bone lesions and certain types of soft tissue abnormalities. X-rays can provide rapid insights into the effectiveness of therapies such as radiation treatment for bone metastases or infections [39].

However, their capacity to quantify treatment response is limited, as they primarily offer qualitative assessments. In cases of bone involvement, X-rays can detect changes in bone density or the presence of new lesions; however, they may not capture subtle changes that could indicate early signs of responding therapy [39].

CT scans have become a standard imaging technique for assessing treatment response, particularly in cancer patients. This modality provides high-resolution, cross-sectional images of the body, allowing clinicians to detect changes in tumor size, morphology, and density post-treatment. The Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, widely acknowledged in clinical oncology, emphasize the measurement of tumor dimensions as a primary parameter for assessing treatment response [40].

One marked advantage of CT imaging is its widespread availability and rapid execution, which is crucial for timely clinical decision-making. However, CT imaging involves exposure to ionizing radiation, a factor that necessitates careful consideration, particularly in patients requiring multiple follow-up scans [40].

MRI has emerged as a vital tool for monitoring therapeutic responses, particularly in soft tissue and central nervous system lesions. This imaging technique offers high contrast between different soft tissues, enhancing the ability to visualize tumors and detect changes in their characteristics over time. MRI is invaluable in evaluating brain tumors, liver lesions, and musculoskeletal abnormalities [41].

Unlike CT scans, MRI does not utilize ionizing radiation, making it a safer alternative for patients requiring multiple follow-ups. However, the challenges associated with MRI include lengthy scanning times and the need for specialized equipment and personnel. Additionally, certain metallic implants or devices may preclude the use of MRI, limiting its applicability in some patients [42].

PET imaging, often used in conjunction with CT (PET/CT), provides unique insights into the metabolic activity of tumors. It utilizes radioactive tracers, typically fluorodeoxyglucose (FDG), which accumulate in metabolically active cells, prominently cancer cells. This characteristic enables PET to detect changes in tumor activity before significant morphological changes appear on CT or MRI [42].

The primary limitation of PET imaging lies in its relative lack of spatial resolution compared to CT or MRI; hence, it is often integrated with other imaging modalities to enhance overall diagnostic accuracy. Nevertheless, PET has proven invaluable in assessing treatment response, particularly in the context of therapy monitoring for lymphomas and other malignancies [43].

Beyond traditional imaging techniques, there are also emerging advanced methodologies such as functional MRI (fMRI), diffusion-weighted imaging (DWI), and PET/MRI that offer enhanced capabilities in treatment response assessment. These advanced techniques work by measuring physiological parameters, such as blood flow, oxygenation, and diffusion characteristics of water molecules in tissues, which can provide additional insights into the effects of therapy.

fMRI assesses brain activity by detecting changes in blood flow, allowing clinicians to evaluate functional changes associated with treatment in brain tumors or other neurological conditions. This technique is particularly useful in research and clinical trials for assessing response to neuro-oncological therapies [43].

DWI is a specialized form of MRI that gauges the diffusion of water molecules within tissues, which can indicate cellular density changes and tumor response. This technique has gained traction in assessing the response of various tumors, particularly gliomas and metastases, to treatment [43].

Despite the myriad benefits that radiological techniques offer, challenges persist in their application for monitoring treatment responses. Factors such as variations in image acquisition protocols, interpretation bias from radiologists, and differences in biological responses among tumors can complicate assessments. A consensus on standardized evaluation criteria remains crucial for ensuring effective communication among multi-disciplinary teams involved in patient management [44].

Additionally, the psychological impact of continuous imaging can induce anxiety in patients, whose treatment responses may fluctuate over time. Addressing these psychosocial aspects is essential in delivering holistic patient care and support.

Challenges and Limitations of Radiological Approaches in Oncology:

Radiology has become an indispensable component in the field of oncology, offering clinicians advanced tools for diagnosis, treatment planning, monitoring therapeutic response, and detecting disease recurrence. Techniques such as X-rays, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, functional imaging (like PET scans), and interventional radiology interventions have vastly improved the management of cancer patients. However, despite the significant advancements, radiological approaches in oncology are accompanied by various challenges and limitations that affect their efficacy and utility. Understanding these obstacles is crucial for enhancing the quality of cancer care and optimizing patient outcomes [45].

One of the primary challenges in radiological oncology is the diagnostic accuracy of imaging techniques. While modalities like CT and MRI provide detailed images of anatomical structures, they can sometimes fall short in distinguishing malignant from benign lesions. For example, both tumors and certain inflammatory processes can present with similar imaging characteristics, leading to potential misdiagnosis. This issue is particularly pronounced in certain cancer types, such as pancreatic or ovarian cancers, which may not be easily visualized through standard imaging protocols [46].

Furthermore, the resolution of imaging can be a limitation; for tumors that are small or in early stages, radiological findings may be negative or inconclusive. This inadequacy not only complicates the initial diagnosis but can also lead to delays in treatment initiation, impacting a patient’s prognosis. In addition, the interpretation of imaging results can be subjective and dependent on the experience of the radiologist. Variability in radiological assessment can result in differing recommendations for treatment [47].

Another significant challenge associated with radiological approaches in oncology is the risk of radiation exposure. While imaging techniques such as X-rays and CT scans are invaluable for diagnosis and treatment, they expose patients to ionizing radiation. Cumulative radiation exposure has been linked to an increased risk of developing secondary malignancies, especially in younger patients or those undergoing multiple imaging studies over time [48].

Radiation dose optimization is an ongoing concern in the field. Although efforts have been made to limit radiation exposure—such as the introduction of low-dose CT scans and advancements in imaging technology—there remains a continuous need for balancing diagnostic yield against the potential risks of radiation. This balance is particularly critical when conducting surveillance imaging in patients who are already cancer survivors, as their risk of secondary malignancies is inherently elevated [49].

The technical limitations associated with various imaging modalities also present challenges in the effective application of radiological approaches in oncology. For instance, MRI is highly sensitive and specific for certain tumors, yet it has limitations such as longer scan times and the need for special patient cooperation. Some patients, particularly those who are claustrophobic or have certain implants, may be unable to undergo MRI [50].

Moreover, the availability of advanced imaging technologies can vary significantly by geographical region. In many parts of the world, particularly in low- and middle-income countries, access to state-of-the-art radiological facilities remains limited. This disparity can affect diagnostic accuracy and the timely initiation of treatment in under-resourced areas, exacerbating health inequalities. Such challenges emphasize the need for the global community to address discrepancies in healthcare access and investment in radiology infrastructure [51].

Effective oncology management often requires the integration of imaging findings with other diagnostic modalities, such as histopathology and molecular testing. However, coordinating these approaches can be challenging. For example, while radiological assessments provide valuable insights into tumor localization and burden, they do not provide information on tumor biology or genetics—factors that are increasingly becoming essential in personalized medicine [51].

This disconnect underscores the limitations of relying solely on radiological evaluations for treatment decisions. For optimal patient management, interdisciplinary collaboration among radiologists, oncologists, pathologists, and other specialists is essential. Such collaboration can lead to enhanced understanding and interpretation of imaging studies in the broader context of each patient's clinical picture [51].

The advent of imaging biomarkers has revolutionized the assessment of treatment response in oncology. However, the limitations of traditional radiological metrics, such as RECIST (Response Evaluation Criteria in Solid Tumors), in capturing the full spectrum of treatment outcomes pose significant challenges. RECIST primarily focuses on tumor size changes, which may not adequately reflect the biological activity of tumors, particularly in the context of newer therapies like immunotherapy [52].

Immunotherapy, for instance, can lead to unique patterns of response, including delayed responses or pseudoprogression, where tumors may initially appear to grow on imaging studies but subsequently shrink. As a result, oncologists may need to rely on additional imaging techniques or functional assessments, such as metabolic imaging with PET scans, to accurately evaluate treatment response. The integration of various imaging modalities and biomarkers is crucial for a comprehensive understanding of tumor dynamics [52].

Despite the numerous challenges and limitations, ongoing innovations in radiological techniques and artificial intelligence (AI) hold the potential to enhance the efficacy and accuracy of imaging in oncology. AI-driven algorithms for image analysis are being developed to assist radiologists in detecting subtle abnormalities and improving diagnostic accuracy. Such advancements could lead to earlier detection of malignancies and more precise treatment planning [53].

Additionally, the ongoing integration of radiomics—the extraction of quantitative features from medical images—and molecular profiling is emerging as a promising avenue. This multidisciplinary approach aims to correlate imaging characteristics with molecular alterations in tumors, thereby facilitating the development of predictive models for treatment response and prognosis [53].

The Evolving Impact of Radiology on Cancer Care:

Radiology has long been an integral component of cancer care, offering critical insights that shape diagnosis, treatment planning, and overall patient management. As technology and methodologies evolve, the impact of radiology on cancer care continues to transform, becoming increasingly precise, personalized, and effective [54].

Radiology's root in oncology can be traced back to the discovery of X-rays in 1895 by Wilhelm Conrad Roentgen. Initially, X-rays were used to detect bone abnormalities, but their application quickly expanded to soft tissues, paving the way for the diagnosis of various malignancies. Over the decades, radiology has adopted numerous imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound. Each advancement has improved the accuracy and detail of imaging, allowing healthcare providers to identify tumors at earlier stages and to delineate their characteristics more clearly [54].

In the mid-20th century, radiation therapy emerged as a direct application of radiological principles in cancer treatment, further establishing radiology as a cornerstone of oncology. The ability to visualize tumors before and after treatment also provided critical feedback for evaluating treatment effectiveness, making imaging an indispensable tool in the multidisciplinary approach to cancer care [55].

Today, the impact of radiology on cancer care is profound, driven by rapid advancements in imaging technologies and techniques. One of the most significant developments has been the move toward more sophisticated imaging technologies such as positron emission tomography (PET) and hybrid imaging systems combining PET with CT (PET/CT) or MRI (PET/MRI). These modalities allow for not only anatomical imaging but also functional imaging, providing insights into tumor metabolism and characteristics that are crucial for accurate staging and monitoring treatment response [55].

Moreover, advancements in artificial intelligence (AI) and machine learning are revolutionizing how radiological images are analyzed. AI algorithms have shown promise in enhancing image interpretation, rapidly identifying abnormalities, and stratifying cancer risk with unprecedented accuracy. For instance, AI-enhanced imaging can reduce the chances of misdiagnosis by alerting radiologists to subtle findings that may otherwise go unnoticed. By integrating AI into radiology workflows, healthcare providers can offer more rapid diagnoses and tailored treatment strategies, ultimately improving patient outcomes [56].

Personalized medicine, which tailors treatment approaches based on individual patient characteristics, is increasingly becoming a dominant paradigm in oncology, and radiology plays a pivotal role in this evolution. Radiomic analyses — the extraction of large amounts of quantitative features from medical images — allow for the characterization of tumors beyond standard measurements. This emerging field enables the stratification of patients based on the biological behavior of tumors, informing decisions about the most appropriate therapeutic interventions [56].

For instance, advanced imaging techniques can help ascertain the heterogeneity within tumors, providing clinicians with insights into not just the presence of cancer but its aggressiveness and potential response to therapies. By integrating imaging biomarkers with genetic and clinical data, radiologists can contribute significantly to the development of personalized treatment plans, moving beyond a “one-size-fits-all” approach in oncology [57].

In addition to its diagnostic and therapeutic functions, radiology is crucial in monitoring treatment response and assessing recurrence risk. Serial imaging allows oncologists to evaluate how well a treatment is working, enabling timely modifications to the treatment plan if necessary. For example, imaging studies can track changes in tumor size and metabolic activity, providing early indications of whether a treatment is having the desired effect [57].

Moreover, advanced imaging techniques are increasingly being employed in the realm of screening and early detection, focusing on high-risk populations. For example, low-dose CT scans for lung cancer screening in smokers have shown to reduce mortality rates, highlighting the radiologist's role in preventive oncology. By identifying malignancies at their earliest stages, radiography can substantially increase survival rates and improve overall public health outcomes [58].

Looking ahead, the future of radiology in cancer care appears bright, with several exciting developments on the horizon. Innovations such as molecular imaging, a technique that allows visualization of biological processes at the molecular and cellular levels, promise to further enhance the precision of cancer diagnosis and treatment. This modality could pave the way for more effective monitoring of treatment responses and lead to the development of novel therapeutic approaches that leverage these insights [59].

Moreover, the integration of telemedicine and remote radiology services has the potential to expand access to expert radiological opinions, particularly in underserved or rural regions. As healthcare systems strive to overcome barriers imposed by geography, tele-radiology could ensure that all patients have access to timely and accurate imaging interpretations, regardless of their location [60].

Furthermore, ongoing research into the development of contrast agents that target specific tumor markers will likely enhance the specificity and sensitivity of imaging modalities, allowing for a more nuanced view of tumor biology. As our understanding of cancer biology continues to improve, the interplay between imaging, genomics, and proteomics will undoubtedly yield more personalized and effective cancer care options [61].

Conclusion:

In conclusion, the influence of radiology in oncology is profound and multifaceted, serving as a cornerstone for modern cancer diagnosis and treatment strategies. As advanced imaging technologies continue to evolve, they provide invaluable insights that enhance the accuracy of tumor characterization, facilitate early detection, and guide targeted therapies. The integration of radiological findings into treatment planning promotes a more personalized approach to oncology, improving patient outcomes through tailored interventions that address the unique characteristics of each tumor.

Moreover, emerging fields such as radiomics are paving the way for even greater precision in cancer management, allowing for the extraction of complex data from imaging studies that can inform treatment decisions and predict responses. While challenges remain, including access to advanced imaging techniques and the need for interdisciplinary collaboration, the ongoing advancements in radiology promise to further revolutionize cancer care. Ultimately, the synergy between radiology and targeted treatment approaches embodies the future of oncology, aiming to optimize therapeutic efficacy while minimizing adverse effects, thereby enhancing the quality of life for patients battling cancer.

References:

1. Njeh CF. Tumor delineation: The weakest link in the search for accuracy in radiotherapy. J Med Phys. 2008;33(4):136–140.
2. Chen AM, Chin R, Beron P, Yoshizaki T, Mikaeilian AG, Cao M. Inadequate target volume delineation and local-regional recurrence after intensity-modulated radiotherapy for human papillomavirus-positive oropharynx cancer. Radiother Oncol. 2017;123(3):412–418.
3. Gregoire V, Evans M, Le QT, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018;126(1):3–24.
4. Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol. 2015;114(1):3–10.
5. Barrett JF, Keat N. Artifacts in CT: recognition and avoidance. Radiographics. 2004;24(6):1679–1691.
6. Vinod SK, Min M, Jameson MG, Holloway LC. A review of interventions to reduce inter-observer variability in volume delineation in radiation oncology. J Med Imaging Radiat Oncol. 2016;60(3):393–406.
7. Pelc NJ. Recent and future directions in CT imaging. Ann Biomed Eng. 2014;42(2):260–268.
8. Landberg T, Chavaudra J, Dobbs J, et al. Report 62. Journal of the International Commission on Radiation Units and Measurements. 2016;os32(1):NP–NP.
9. Nestle U, De Ruysscher D, Ricardi U, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol. 2018;127(1):1–5.
10. Khan FM, Sperduto PW. Khan's Treatment Planning in Radiation Oncology. Wolters Kluwer; 2016; ISBN 9781469889979.
11. Salembier C, Villeirs G, De Bari B, et al. ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol. 2018;127(1):49–61.
12. Chang ATY, Tan LT, Duke S, Ng WT. Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials. Front Oncol. 2017;7:221.
13. Kontaxis C, Bol GH, Stemkens B, et al. Towards fast online intrafraction replanning for free-breathing stereotactic body radiation therapy with the MR-linac. Phys Med Biol. 2017;62(18):7233–7248.
14. Vinod SK, Jameson MG, Min M, Holloway LC. Uncertainties in volume delineation in radiation oncology: A systematic review and recommendations for future studies. Radiother Oncol. 2016;121(2):169–179.
15. Rasch C, Steenbakkers R, van Herk M. Target definition in prostate, head, and neck. Semin Radiat Oncol. 2005;15(3):136–145.
16. Bushberg JT, Leidholdt EM, Seibert JA. Essential Physics of Medical Imaging. Wolters Kluwer; 2011; ISBN 9781451118100.
17. Saw CB, Loper A, Komanduri K, Combine T, Huq S, Scicutella C. Determination of CT-to-

density conversion relationship for image-based treatment planning systems. Med Dosim. 2005;30(3):145–148.

18. Peters LJ, O'Sullivan B, Giralt J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol. 2010;28(18):2996–3001.
19. Li XA, Tai A, Arthur DW, et al. Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study. International journal of radiation oncology, biology, physics. 2009;73(3):944–951.
20. Onal C, Cengiz M, Guler OC, Dolek Y, Ozkok S. The role of delineation education programs for improving interobserver variability in target volume delineation in gastric cancer. Br J Radiol. 2017;90(1073):20160826.
21. Report 83. Journal of the International Commission on Radiation Units and Measurements. 2016;10(1):NP–NP.
22. FDA. VENTANA PD-L1 (SP142) assay - P160002/ S009, 2020.
23. Jadvar H, Chen X, Cai W & Mahmood U. Radiotheranostics in cancer diagnosis and management. Radiology 286, 388–400 (2018).
24. Grillo-Lopez AJ. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert. Rev. Anticancer. Ther 2, 485–493 (2002).
25. Park S et al. Somatostatin receptor imaging and theranostics: current practice and future prospects. J. Nucl. Med 62, 1323–1329 (2021).
26. Pouget JP, Catherine L, Deshayes E, Boudousq V & Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy. Front. Med 2, 12 (2015).
27. Friedberg JW & Fisher RI. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert. Rev. Anticancer. Ther 4, 18–26 (2004).
28. Ku A, Facca VJ, Cai Z & Reilly RM. Auger electrons for cancer therapy - a review. EJNMMI Radiopharm. Chem 4, 27 (2019).
29. Witzig TE et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol 15, 2453–2463 (2002).
30. Seidlin SM, Marinelli LD & Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J. Am. Med. Assoc 132, 838–847 (1946).
31. Herrmann K et al. Radiotheranostics: a roadmap for future development. Lancet Oncol 21, e146–e156 (2020).
32. Garin E et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol. Hepatol 6, 17–29 (2021).
33. Poty S, Francesconi LC, McDevitt MR, Morris MJ & Lewis JS. Alpha-emitters for radiotherapy: from basic radiochemistry to clinical studies-part 1. J. Nucl. Med 59, 878–884 (2018).
34. Adams DJ. The valley of death in anticancer drug development: a reassessment. Trends Pharmacol. Sci 33, 173–180 (2012).
35. Leahy MF, Seymour JF, Hicks RJ & Rurner JH. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J. Clin. Oncol 20, 4418–4425 (2006).
36. Hertz S, Roberts A & Evans RD. Radioactive iodine as an indicator in the study of thyroid physiology. Proc. Soc. Exp. Biol. Med 38, 510–513 (1938).
37. Sgouros G, Bodei L, McDevitt MR & Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat. Rev. Drug Discov 19, 589–608 (2020).
38. NCCN. NCCN Guidelines, 2021.
39. Pouget JP et al. From the target cell theory to a more integrated view of radiobiology in

targeted radionuclide therapy: the Montpellier group's experience. Nucl. Med/ Biol 104–105, 53–64 (2022).

40. Chapman EM & Evans RD. The treatment of hyperthyroidism with radioactive iodine. J. Am. Med. Assoc 131, 86–91 (1946).
41. Ferrucci PF et al. High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. Br. J. Haematol 139, 590–599 (2007).
42. Giraud P, Garcia R. Respiratory gating for radiotherapy: main technical aspects and clinical benefits. Bull Cancer. 2010;97(7):847–856.
43. Remy C, Lalonde A, Beliveau-Nadeau D, Carrier JF, Bouchard H. Dosimetric impact of dual-energy CT tissue segmentation for low-energy prostate brachytherapy: a Monte Carlo study. Phys Med Biol. 2018;63(2):025013.
44. Wee CW, An HJ, Kang HC, Kim HJ, Wu HG. Variability of Gross Tumor Volume Delineation for Stereotactic Body Radiotherapy of the Lung With Tri-(60)Co Magnetic Resonance Image-Guided Radiotherapy System (ViewRay): A Comparative Study With Magnetic Resonance- and Computed Tomography-Based Target Delineation. Technol Cancer Res Treat. 2018;17:1533033818787383.
45. Al-Hammadi N, Caparrotti P, Divakar S, et al. MRI Reduces Variation of Contouring for Boost Clinical Target Volume in Breast Cancer Patients Without Surgical Clips in the Tumour Bed. Radiol Oncol. 2017;51(2):160–168.
46. Evans PM. Anatomical imaging for radiotherapy. Phys Med Biol. 2008;53(12):R151–191.
47. Li G, Citrin D, Camphausen K, et al. Advances in 4D medical imaging and 4D radiation therapy. Technol Cancer Res Treat. 2008;7(1):67–81.
48. Wang L, Hayes S, Paskalev K, et al. Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: evaluation of the impact on daily dose coverage. Radiother Oncol. 2009;91(3):314–324.
49. Jensen NK, Mulder D, Lock M, et al. Dynamic contrast enhanced CT aiding gross tumor volume delineation of liver tumors: an interobserver variability study. Radiother Oncol. 2014;111(1):153–157.
50. Pessis E, Sverzut JM, Campagna R, Guerini H, Feydy A, Drape JL. Reduction of Metal Artifact with Dual-Energy CT: Virtual Monospectral Imaging with Fast Kilovoltage Switching and Metal Artifact Reduction Software. Semin Musculoskelet Radiol. 2015;19(5):446–455.
51. Geets X, Daisne JF, Arcangeli S, et al. Inter-observer variability in the delineation of pharyngo-laryngeal tumor, parotid glands and cervical spinal cord: comparison between CT-scan and MRI. Radiother Oncol. 2005;77(1):25–31.
52. Al-Hammadi N, Caparrotti P, Divakar S, et al. MRI Reduces Variation of Contouring for Boost Clinical Target Volume in Breast Cancer Patients Without Surgical Clips in the Tumour Bed. Radiol Oncol. 2017;51(2):160–168.
53. Coursey CA, Nelson RC, Boll DT, et al. Dual-energy multidetector CT: how does it work, what can it tell us, and when can we use it in abdominopelvic imaging? Radiographics. 2010;30(4):1037–1055.
54. Beddar AS, Briere TM, Balter P, et al. 4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. Radiother Oncol. 2008;87(3):445–448.
55. O'Connor JP, Tofts PS, Miles KA, Parkes LM, Thompson G, Jackson A. Dynamic contrast-enhanced imaging techniques: CT and MRI. Br J Radiol. 2011;84 Spec No 2:S112–120.
56. Al-Hammadi N, Caparrotti P, Divakar S, et al. MRI Reduces Variation of Contouring for Boost Clinical Target Volume in Breast Cancer Patients Without Surgical Clips in the Tumour Bed. Radiol Oncol. 2017;51(2):160–168.
57. Wang JZ, Li JB, Qi HP, et al. Effect of contrast enhancement in delineating GTV and constructing IGTV of thoracic oesophageal

cancer based on 4D-CT scans. Radiother Oncol. 2016;119(1):172–178.

58. Kovacs DG, Rechner LA, Appelt AL, et al. Metal artefact reduction for accurate tumour delineation in radiotherapy. Radiother Oncol. 2018;126(3):479–486.

59. Al-Hammadi N, Caparrotti P, Divakar S, et al. MRI Reduces Variation of Contouring for Boost Clinical Target Volume in Breast Cancer Patients Without Surgical Clips in the Tumour Bed. Radiol Oncol. 2017;51(2):160–168.

60. Ginat DT, Mayich M, Daftari-Besheli L, Gupta R. Clinical applications of dual-energy CT in head and neck imaging. Eur Arch Otorhinolaryngol. 2016;273(3):547–553.

61. van Elmpt W, Landry G, Das M, Verhaegen F. Dual energy CT in radiotherapy: Current applications and future outlook. Radiother Oncol. 2016;119(1):137–144.